查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1632667

全球分叉病变市场：市场规模、份额、趋势分析（按应用和地区）、细分市场预测（2025-2030 年）

Bifurcation Lesions Market Size, Share & Trends Analysis Report, By Application (Coronary, Peripheral), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

分叉市场的成长和趋势：

根据 Grand View Research, Inc. 的一份新报告，全球分叉病变市场规模预计到 2030 年将达到 35 亿美元，2025 年至 2030 年的复合年增长率为 6.0%。

在预测期内，政府对技术开发和报销的支持倡议可能会推动市场发展。

老龄人口的增加和不健康的生活方式是导致心血管疾病发生率不断上升的原因。此外，未来几年创新设备的核准和商业化程度不断提高，以及预计用于治疗分叉病变的新设备的进入，可能会推动市场的发展。

此外，负担能力上升、微创手术需求增加、医疗旅游崛起等因素也推动了全球整体对分叉病变手术的需求。根据多项研究，分叉病变手术约占所有经皮冠状动脉介入治疗的20%。

分叉病变市场：概述

  • 分叉病变设备日益商业化以及产业参与者对研发的投资正在推动市场的发展，预计 2025 年至 2030 年期间复合年增长率约为 6.0%。
  • 由于心臟内血管网络复杂、设备可用性不断提高以及对分叉病变手术干预的认识不断提高，冠状血管部分在 2024 年占据了最大的市场份额。
  • 由于产业参与者对週边应用设备开发的投资不断增加，以及诊断技术的进步使得斑块的准确检测成为可能，週边血管领域在未来几年可能会呈现丰厚的成长。
  • 按地区划分，北美将在 2024 年占据分叉病变市场的最大份额。由于药物释放型支架的需求不断增加、分叉病变设备的商业化以及主要企业在该地区的扩张，预计未来它将保持主导地位。
  • 由于医疗保健基础设施的改善、媒体驱动的旅游业以及参与企业不断增加的投资，亚太地区预计将成为未来十年成长最快的地区。
  • 市场的主要企业包括雅培、波士顿科学、康德乐、美Medtronic力、强生服务公司、CR Bard、Spectranetics 和Terumo Medical Corp.。开发了 Tryton 侧支支架，该支架具有球囊扩张单丝支架输送系统，可放置在侧支动脉中治疗分叉病变。该支架已在美国、欧洲、中东和非洲销售。

目录

第一章 分析方法及范围

第 2 章执行摘要

第 3 章 分叉病变市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 分岔市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL 分析

第 4 章 分叉病变市场：按应用的估计和趋势分析

  • 分岔市场：应用仪表板
  • 分叉病变市场：应用趋势分析
  • 分叉病变市场：按应用分類的市场规模预测和趋势分析（2018-2030 年）
  • 冠状动脉
  • 周围血管

第五章 分叉病变市场：区域估计和趋势分析（按应用和地区）

  • 全球分叉病变市场：区域仪表板
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第六章 竞争格局

  • 最新趋势和影响分析：按主要製造商
  • 公司/竞争对手分类
  • 供应商概况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 主要企业市场占有率分析（2023年）
    • Boston Scientific Corp.
    • Abbott
    • Cardinal Health
    • Medtronic
    • CR Bard, Inc.
    • Johnson &Johnson Services, Inc.
    • Spectranetics
    • Terumo Medical Corp.
    • Tryton Medical Inc.
Product Code: GVR-1-68038-534-2

Bifurcation Lesions Market Growth & Trends:

The global bifurcation lesions market size is expected to reach USD 3.5 billion by 2030, registering a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological developments and supportive government initiatives for reimbursement are likely to drive the market during the forecast period.

The increasing geriatric population and unhealthy lifestyle are responsible for growth in the incidence of cardiovascular disorders. Furthermore, an increase in approval & commercialization of innovative devices and the expected entry of new devices for the treatment of bifurcation lesions in the coming years are likely to drive the market.

In addition, factors such as rising affordability, increase in demand for minimally invasive procedures, and growing medical tourism are also boosting demand for bifurcation lesions procedures across the globe. According to various studies, procedures for coronary bifurcation lesions comprise approximately 20% of total percutaneous coronary interventions.

Bifurcation Lesions Market Report Highlights:

  • Increase in the commercialization of devices for bifurcation lesions and investments by industry players for R&D are the factors expected to boost the market, resulting in an anticipated CAGR of around 6.0% from 2025 to 2030
  • The coronary vascular segment accounted for the maximum share of the market in 2024 due to the presence of complex vascular network in heart, increased availability of devices, and rise in awareness regarding surgical interventions for bifurcation lesions.
  • The peripheral vascular segment is likely to witness lucrative growth in the coming years due to an increase in investments by industry players for the development of devices for peripheral application and advancements in diagnostics facilitating accurate detection of plaque.
  • Geographically, North America held the largest share of the bifurcation lesions market in 2024. It is anticipated to maintain its dominance in the coming years due to increasing demand for drug-eluting stents, commercialization of devices for bifurcation lesions, and the local presence of major market players.
  • The Asia Pacific is expected to observe the fastest growth over the next decade owing to improvement in healthcare infrastructure, medical tourism, and a rise in investments by market players in the region.
  • Some of the key players in the market are Abbott; Boston Scientific Corporation; Cardinal Health; Medtronic; Johnson & Johnson Services, Inc.; C. R. Bard, Inc.; Spectranetics; and Terumo Medical Corporation. Tryton Medical, Inc. developed the Tryton Side Branch Stent with a balloon-expandable, single-wire stent delivery system that can be deployed in the side branch artery for treatment of bifurcation lesions. The device is available in the U.S. and Europe as well as Middle East & Africa.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecast timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity price analysis (Model 1)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application Segment
    • 2.2.2. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Bifurcation Lesions Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of congenital heart disease
      • 3.2.1.2. Increasing number of CVD incidence
      • 3.2.1.3. Increasing awareness among the population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Limited awareness and adoption
  • 3.3. Bifurcation Lesions Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Bifurcation Lesions Market: Application Estimates & Trend Analysis

  • 4.1. Bifurcation Lesions Market: Application Dashboard
  • 4.2. Bifurcation Lesions Market: Application Movement Analysis
  • 4.3. Bifurcation Lesions Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. Coronary
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Peripheral
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Bifurcation Lesions Market: Regional Estimates & Trend Analysis by Application, and Region

  • 5.1. Global Bifurcation Lesions Market: Regional Dashboard
  • 5.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 5.3. North America
    • 5.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Regulatory framework/ reimbursement structure
      • 5.3.2.3. Competitive scenario
      • 5.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Regulatory framework/ reimbursement structure
      • 5.3.3.3. Competitive scenario
      • 5.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.4. Mexico
      • 5.3.4.1. Key country dynamics
      • 5.3.4.2. Regulatory framework/ reimbursement structure
      • 5.3.4.3. Competitive scenario
      • 5.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4. Europe
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.4.2. UK
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework/ reimbursement structure
      • 5.4.2.3. Competitive scenario
      • 5.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.3. Germany
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework/ reimbursement structure
      • 5.4.3.3. Competitive scenario
      • 5.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.4. France
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Regulatory framework/ reimbursement structure
      • 5.4.4.3. Competitive scenario
      • 5.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.5. Italy
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Regulatory framework/ reimbursement structure
      • 5.4.5.3. Competitive scenario
      • 5.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.6. Spain
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Regulatory framework/ reimbursement structure
      • 5.4.6.3. Competitive scenario
      • 5.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Key country dynamics
      • 5.4.7.2. Regulatory framework/ reimbursement structure
      • 5.4.7.3. Competitive scenario
      • 5.4.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Key country dynamics
      • 5.4.8.2. Regulatory framework/ reimbursement structure
      • 5.4.8.3. Competitive scenario
      • 5.4.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.9. Denmark
      • 5.4.9.1. Key country dynamics
      • 5.4.9.2. Regulatory framework/ reimbursement structure
      • 5.4.9.3. Competitive scenario
      • 5.4.9.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.5.2. China
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.3. Japan
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework/ reimbursement structure
      • 5.5.3.3. Competitive scenario
      • 5.5.3.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.4. India
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework/ reimbursement structure
      • 5.5.4.3. Competitive scenario
      • 5.5.4.4. India market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.5. Australia
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework/ reimbursement structure
      • 5.5.5.3. Competitive scenario
      • 5.5.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.6. Thailand
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework/ reimbursement structure
      • 5.5.6.3. Competitive scenario
      • 5.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.7. South Korea
      • 5.5.7.1. Key country dynamics
      • 5.5.7.2. Regulatory framework/ reimbursement structure
      • 5.5.7.3. Competitive scenario
      • 5.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6. Latin America
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Brazil
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7. MEA
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.7.3. South Africa
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.7.4. UAE
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework/ reimbursement structure
      • 5.7.4.3. Competitive scenario
      • 5.7.4.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.7.5. Kuwait
      • 5.7.5.1. Key country dynamics
      • 5.7.5.2. Regulatory framework/ reimbursement structure
      • 5.7.5.3. Competitive scenario
      • 5.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key company market share analysis, 2023
    • 6.3.4. Boston Scientific Corp.
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Abbott
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. Cardinal Health
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Medtronic
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. C. R. Bard, Inc.
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. Johnson & Johnson Services, Inc.
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. Spectranetics
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives
    • 6.3.11. Terumo Medical Corp.
      • 6.3.11.1. Company overview
      • 6.3.11.2. Financial performance
      • 6.3.11.3. Product benchmarking
      • 6.3.11.4. Strategic initiatives
    • 6.3.12. Tryton Medical Inc.
      • 6.3.12.1. Company overview
      • 6.3.12.2. Financial performance
      • 6.3.12.3. Product benchmarking
      • 6.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 Global bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 4 Global bifurcation lesions market, by region, 2018 - 2030 (USD Million)
  • Table 5 North America bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 7 U.S. bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 9 Mexico bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 10 Europe bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 12 UK bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 13 Germany bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 14 France bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 15 Italy bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 16 Spain bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 17 Denmark bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 18 Sweden bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 19 Norway bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 22 Japan bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 23 China bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 24 India bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 25 Australia bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 26 Australia bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 27 Thailand bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 28 South Korea bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 29 Latin America bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 30 Latin America bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 31 Brazil bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 32 Argentina bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 33 MEA bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 34 MEA bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 35 South Africa bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 36 Saudi Arabia bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 37 UAE bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 38 Kuwait bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 39 Participant's overview
  • Table 40 Financial performance
  • Table 41 Key companies undergoing expansions
  • Table 42 Key companies undergoing acquisitions
  • Table 43 Key companies undergoing collaborations
  • Table 44 Key companies launching new product types
  • Table 45 Key companies undergoing partnerships
  • Table 46 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Bifurcation lesions market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Bifurcation lesions market outlook, 2024 (USD Million)
  • Fig. 10 Market Trends & outlook
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 Bifurcation lesions application market share analysis, 2024 - 2030 (USD Million)
  • Fig. 14 Bifurcation lesions application market: Segment dashboard
  • Fig. 15 Coronary market, 2018 - 2030 (USD Million)
  • Fig. 16 Peripheral market, 2018 - 2030 (USD Million)
  • Fig. 17 Regional marketplace: Key takeaways
  • Fig. 18 North America bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 20 Canada bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 21 Mexico bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 22 Europe bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 23 UK bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 24 Germany bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 25 France bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 26 Italy bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 27 Spain bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 28 Denmark bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 29 Sweden bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 30 Norway bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 31 Asia Pacific bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 32 Japan bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 33 China bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 34 India bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 35 Australia bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 36 South Africa bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 37 Thailand bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 38 Latin America bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 39 Brazil bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 40 Argentina bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 41 MEA bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 42 South Africa bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 43 Saudi Arabia bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 44 UAE bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 45 Kuwait bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 46 Strategy framework